{
  "id": 5065,
  "text": "Paclitaxel has moderate activity in squamous cervix cancer.A Gynecologic Oncology Group study.J Clin Oncol 996;14:792-795.1 Marabelle A, Le DT, Ascierto PA, et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: esults from the phase 2 KEYNOTE-158 study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Paclitaxel has moderate activity in squamous cervix cancer.A Gynecologic Oncology Group study.J Clin Oncol 996;14:792-795.1 Marabelle A, Le DT, Ascierto PA, et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: esults from the phase 2 KEYNOTE-158 study.\n\n<question>: ",
  "ChatGPT_response_0": "在 KEYNOTE-158 研究中，Pembrolizumab 在非结直肠高微卫星不稳定/错配修复缺陷癌症患者中显示了一定的疗效。研究结果表明，在这些患者中，Pembrolizumab 的治疗效果是积极的。这表明免疫检查点抑制剂Pembrolizumab在治疗非结直肠高微卫星不稳定/错配修复缺陷癌症患者中可能具有潜在的临床益处，尤其对于那些对传统疗法难以控制的患者可能是一种有效的治疗选择。值得注意的是，患者在接受该治疗时可能会出现一些特定的不良反应，因此医生应该根据患者的具体情况进行全面评估和个性化治疗。如果您或您认识的人患有类似状况，建议咨询专业医生以获取更详细的建议和治疗方案。",
  "query": "在妇科肿瘤研究中，植物生物碱对宫颈鳞癌有中等活性。请问在 KEYNOTE-158 研究中，Pembrolizumab 在非结直肠高微卫星不稳定/错配修复缺陷癌症患者中的疗效如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在妇科肿瘤研究中，植物生物碱对宫颈鳞癌有中等活性。请问在 KEYNOTE-158 研究中，Pembrolizumab 在非结直肠高微卫星不稳定/错配修复缺陷癌症患者中的疗效如何？\n\n<reference text>: Paclitaxel has moderate activity in squamous cervix cancer.A Gynecologic Oncology Group study.J Clin Oncol 996;14:792-795.1 Marabelle A, Le DT, Ascierto PA, et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: esults from the phase 2 KEYNOTE-158 study.\n\n<reply>: ",
  "response": "在 KEYNOTE-158 研究中，Pembrolizumab 在非结直肠高微卫星不稳定/错配修复缺陷癌症患者中显示了一定的疗效。研究结果表明，在这些患者中，Pembrolizumab 的治疗效果是积极的。这表明免疫检查点抑制剂Pembrolizumab在治疗非结直肠高微卫星不稳定/错配修复缺陷癌症患者中可能具有潜在的临床益处，尤其对于那些对传统疗法难以控制的患者可能是一种有效的治疗选择。值得注意的是，患者在接受该治疗时可能会出现一些特定的不良反应，因此医生应该根据患者的具体情况进行全面评估和个性化治疗。如果您或您认识的人患有类似状况，建议咨询专业医生以获取更详细的建议和治疗方案。"
}